{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:08:20Z","timestamp":1789402100291,"version":"build-2803163510"},"posted":{"date-parts":[[2026,4,24]]},"group-title":"In Review","reference-count":54,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,3,23]]},"abstract":"<title>Abstract<\/title>\n                <p>Background:\n Patients with prostate cancer who develop androgen pathway modulation resistant (APMR) disease face lethal outcomes despite advances in androgen receptor\u2013pathway inhibitors, chemotherapy, and PSMA-directed radioligands. Antibody\u2013drug conjugates (ADCs) have demonstrated transformative efficacy in multiple malignancies, yet ADCs evaluated in patients with metastatic APMR have largely focused on direct tumor cytotoxicity without assessing immune mechanisms that may underpin durable therapeutic responses. Whether immune activation contributes to ADC efficacy in prostate cancer remains unexplored.\nMethods:\n We applied immune-centric design principles to ADC development targeting six transmembrane epithelial antigen of the prostate 1 (STEAP1), a prostate-lineage restricted, androgen receptor\u2013regulated surface antigen. vandortuzumab-based ADCs were generated using multiple clinically validated linker\u2013payload platforms. Constructs were evaluated using in vitro assays of Fc\u03b3 receptor engagement, antigen presentation, and T-cell activation, followed by in vivo testing in bone-metastatic and syngeneic immunocompetent APMR models.\nResults:\n STEAP1 specific Fc\u03b3 receptor engagement was required for optimal antigen presentation and downstream T-cell activation. Among tested payloads, exatecan-based ADCs demonstrated the strongest immunostimulatory activity. In bone-metastatic and immunocompetent APMR models, vandortuzumab\u2013exatecan mediated durable tumor control and induced adaptive immune memory capable of preventing tumor rechallenge.\nConclusions:\n These findings identify immune activation as an important determinant of ADC efficacy in APMR and demonstrate that vandortuzumab\u2013exatecan functions as an immune-engaging ADC capable of inducing durable anti-tumor responses. Incorporating immune activation into ADC design may improve the therapeutic potential of ADCs for patients with advanced prostate cancer.<\/p>","DOI":"10.21203\/rs.3.rs-9194287\/v1","type":"posted-content","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:49:19Z","timestamp":1776991759000},"source":"Crossref","is-referenced-by-count":0,"title":["Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory Properties"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7191-0437","authenticated-orcid":false,"given":"John Shuhan","family":"Wang","sequence":"first","affiliation":[{"name":"Duke University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirajbir S.","family":"Sodhi","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Chung","family":"Tsao","sequence":"additional","affiliation":[{"name":"Duke University Department of Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang Han","family":"Lin","sequence":"additional","affiliation":[{"name":"Duke University Graduate School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Moon","sequence":"additional","affiliation":[{"name":"Duke University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Xavier University of Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushangqing","family":"Liu","sequence":"additional","affiliation":[{"name":"Duke University Graduate School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Penaranda","sequence":"additional","affiliation":[{"name":"Duke University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy N.","family":"Trotter","sequence":"additional","affiliation":[{"name":"Duke University Department of Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Somarelli","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Kim","family":"Lyerly","sequence":"additional","affiliation":[{"name":"Duke University Department of Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangdi","family":"Wang","sequence":"additional","affiliation":[{"name":"Xavier University of Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6549-8207","authenticated-orcid":false,"given":"Zachary C.","family":"Hartman","sequence":"additional","affiliation":[{"name":"Duke University Department of Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/d41573-024-00064-w","article-title":"The antibody-drug conjugate landscape","volume":"23","author":"Flynn P","year":"2024","unstructured":"Flynn P, Suryaprakash S, Grossman D, Panier V, Wu J. The antibody-drug conjugate landscape. Nat Rev Drug Discov. 2024;23:577\u20138. https:\/\/doi.org:10.1038\/d41573-024-00064-w.","journal-title":"Nat Rev Drug Discov"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich's magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt K","year":"2008","unstructured":"Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8:473\u201380. https:\/\/doi.org:10.1038\/nrc2394.","journal-title":"Nat Rev Cancer"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz SA","year":"2023","unstructured":"Hurvitz SA, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401:105\u201317. https:\/\/doi.org:10.1016\/S0140-6736(22)02420-5.","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study","volume":"43","author":"Sands J","year":"2025","unstructured":"Sands J, et al. Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study. J Clin Oncol. 2025;43:1254\u201365. https:\/\/doi.org:10.1200\/JCO-24-01349.","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1200\/JCO.24.00646","article-title":"Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer","volume":"43","author":"Swiecicki PL","year":"2025","unstructured":"Swiecicki PL, et al. Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer. J Clin Oncol. 2025;43:578\u201388. https:\/\/doi.org:10.1200\/JCO.24.00646.","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1200\/JCO.19.00646","article-title":"Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer","volume":"37","author":"Danila DC","year":"2019","unstructured":"Danila DC, et al. Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019;37:3518\u201327. https:\/\/doi.org:10.1200\/JCO.19.00646.","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5111","article-title":"Powderly II Phase 1, open-label, first-in-human study of ABBV-969, a dual variable antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer","volume":"43","author":"Anthony W","year":"2025","unstructured":"Anthony W, Tolcher TBD, Okubo S, Abraham L, Reilly R, Stevenson C, Wang S, Cole A, Mudd S, Alaei S, Wang Y, Quinn DI, Saad F. Powderly II Phase 1, open-label, first-in-human study of ABBV-969, a dual variable antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2025;43:43. https:\/\/doi.org:10.1200\/JCO.2025.43.16_suppl.TPS5111.","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-1159","author":"Pia M","year":"2025","unstructured":"; Albert Goldson; Erin Nye; Alexis Mahloch; Maojun Guo; Alex Chu-Kung; Dong Jun Lee; Hui Li; Sabine Rottmann, Pia M, Challita-Eid MSA. M. H. O. B. F. A. S. J. P. D. A. Y. W. P. P. C. K. Z. M. M.-K. Abstract 1159: Preclinical characterization of a novel STEAP1 antibody-drug conjugate ADRX-0405 for the treatment of mCRPC. Cancer Research, 1159 (2025). https:\/\/doi.org:https:\/\/doi.org\/10.1158\/1538-7445.AM2025-1159"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1158\/2159-8290.CD-23-0984","article-title":"AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2\u2009+\u20091 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer","volume":"14","author":"Nolan-Stevaux O","year":"2024","unstructured":"Nolan-Stevaux O, et al. AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2\u2009+\u20091 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer. Cancer Discov. 2024;14:90\u2013103. https:\/\/doi.org:10.1158\/2159-8290.CD-23-0984.","journal-title":"Cancer Discov"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 x CD3 XmAb 2\u2009+\u20091 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study","volume":"14","author":"Kelly WK","year":"2024","unstructured":"Kelly WK, et al. Xaluritamig, a STEAP1 x CD3 XmAb 2\u2009+\u20091 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov. 2024;14:76\u201389. https:\/\/doi.org:10.1158\/2159-8290.CD-23-0964.","journal-title":"Cancer Discov"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41467-023-37874-2","article-title":"Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy","volume":"14","author":"Bhatia V","year":"2023","unstructured":"Bhatia V, et al. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Nat Commun. 2023;14:2041. https:\/\/doi.org:10.1038\/s41467-023-37874-2.","journal-title":"Nat Commun"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.155636","article-title":"Trastuzumab\/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis","volume":"7","author":"Tsao LC","year":"2022","unstructured":"Tsao LC, et al. Trastuzumab\/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis. JCI Insight. 2022;7. https:\/\/doi.org:10.1172\/jci.insight.155636.","journal-title":"JCI Insight"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.131882","article-title":"CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis","volume":"4","author":"Tsao LC","year":"2019","unstructured":"Tsao LC, et al. CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. JCI Insight. 2019;4. https:\/\/doi.org:10.1172\/jci.insight.131882.","journal-title":"JCI Insight"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/1479-5876-11-307","article-title":"Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2\/neu breast cancer patients","volume":"11","author":"Petricevic B","year":"2013","unstructured":"Petricevic B, et al. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2\/neu breast cancer patients. J Transl Med. 2013;11:307. https:\/\/doi.org:10.1186\/1479-5876-11-307.","journal-title":"J Transl Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao LC","year":"2025","unstructured":"Tsao LC, et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat Commun. 2025;16:3167. https:\/\/doi.org:10.1038\/s41467-025-58266-8.","journal-title":"Nat Commun"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s12282-024-01600-7","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable\/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study","volume":"31","author":"Yamashita T","year":"2024","unstructured":"Yamashita T, et al. Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable\/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study. Breast Cancer. 2024;31:858\u201368. https:\/\/doi.org:10.1007\/s12282-024-01600-7.","journal-title":"Breast Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1741","author":"Berger R","year":"2024","unstructured":"Berger R, Dorff AWTTB, Okubo S, Abraham LS, Reilly R, Stevenson C, Wang S, Arnold J, Mudd SR, Alaei S, Hong J, Quinn DI, Saad F. J. Powderly. 1660TiP First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology Volume 35, S1000-S1001 (2024). https:\/\/doi.org:10.1016\/j.annonc.2024.08.1741"},{"key":"ref18","author":"AdcentrxTherapeutics","year":"2024","unstructured":"AdcentrxTherapeutics. A Phase 1a\/b Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors, <https:\/\/www.clinicaltrials.gov\/study\/NCT06710379 (2024)."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccell.2021.11.004","article-title":"Elimination of fluorescent protein immunogenicity permits modeling of metastasis in immune-competent settings","volume":"40","author":"Grzelak CA","year":"2022","unstructured":"Grzelak CA, et al. Elimination of fluorescent protein immunogenicity permits modeling of metastasis in immune-competent settings. Cancer Cell. 2022;40:1\u20132. https:\/\/doi.org:10.1016\/j.ccell.2021.11.004.","journal-title":"Cancer Cell"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1158\/2767-9764.CRC-24-0062","article-title":"Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent NoGlow Mice","volume":"4","author":"Trotter TN","year":"2024","unstructured":"Trotter TN, et al. Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent NoGlow Mice. Cancer Res Commun. 2024;4:1050\u201362. https:\/\/doi.org:10.1158\/2767-9764.CRC-24-0062.","journal-title":"Cancer Res Commun"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/cancers12102804","article-title":"Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer","author":"Haughey CM","year":"2020","unstructured":"Haughey CM, et al. Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer. Cancers (Basel). 2020;12. https:\/\/doi.org:10.3390\/cancers12102804.","journal-title":"Cancers (Basel)"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"eadk1894","DOI":"10.1126\/sciadv.adk1894","article-title":"Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data","volume":"10","author":"Rubahamya B","year":"2024","unstructured":"Rubahamya B, Dong S, Thurber GM. Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data. Sci Adv. 2024;10:eadk1894. https:\/\/doi.org:10.1126\/sciadv.adk1894.","journal-title":"Sci Adv"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1158\/0008-5472.CAN-12-4213","article-title":"Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee","volume":"73","author":"Ittmann M","year":"2013","unstructured":"Ittmann M, et al. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 2013;73:2718\u201336. https:\/\/doi.org:10.1158\/0008-5472.CAN-12-4213.","journal-title":"Cancer Res"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.bmcl.2016.02.020","article-title":"Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads","volume":"26","author":"Nakada T","year":"2016","unstructured":"Nakada T, et al. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads. Bioorg Med Chem Lett. 2016;26:1542\u20135. https:\/\/doi.org:10.1016\/j.bmcl.2016.02.020.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/abt\/tbaf005","article-title":"Fundamental properties and principal areas of focus in antibody-drug conjugates formulation development","volume":"8","author":"Wen L","year":"2025","unstructured":"Wen L, et al. Fundamental properties and principal areas of focus in antibody-drug conjugates formulation development. Antib Ther. 2025;8:99\u2013110. https:\/\/doi.org:10.1093\/abt\/tbaf005.","journal-title":"Antib Ther"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1158\/0008-5472.CAN-20-4028","article-title":"Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer","volume":"81","author":"El-Kenawi A","year":"2021","unstructured":"El-Kenawi A, et al. Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer. Cancer Res. 2021;81:5477\u201390. https:\/\/doi.org:10.1158\/0008-5472.CAN-20-4028.","journal-title":"Cancer Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e0245638","DOI":"10.1371\/journal.pone.0245638","article-title":"Pixelwise H-score: A novel digital image analysis-based metric to quantify membrane biomarker expression from immunohistochemistry images","volume":"16","author":"Ram S","year":"2021","unstructured":"Ram S, et al. Pixelwise H-score: A novel digital image analysis-based metric to quantify membrane biomarker expression from immunohistochemistry images. PLoS ONE. 2021;16:e0245638. https:\/\/doi.org:10.1371\/journal.pone.0245638.","journal-title":"PLoS ONE"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jim.2019.03.001","article-title":"A novel method for determining antibody-dependent cellular phagocytosis","volume":"468","author":"Kamen L","year":"2019","unstructured":"Kamen L, et al. A novel method for determining antibody-dependent cellular phagocytosis. J Immunol Methods. 2019;468:55\u201360. https:\/\/doi.org:10.1016\/j.jim.2019.03.001.","journal-title":"J Immunol Methods"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro R","year":"2017","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14:417\u20139. https:\/\/doi.org:10.1038\/nmeth.4197.","journal-title":"Nat Methods"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.7563.2","author":"Soneson C","year":"2015","unstructured":"Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res 4, 1521 (2015). https:\/\/doi.org:10.12688\/f1000research.7563.2"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love MI","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. https:\/\/doi.org:10.1186\/s13059-014-0550-8.","journal-title":"Genome Biol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"100141","DOI":"10.1016\/j.xinn.2021.100141","article-title":"clusterProfiler 4.0: A universal enrichment tool for interpreting omics data","volume":"2","author":"Wu T","year":"2021","unstructured":"Wu T, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innov (Camb). 2021;2:100141. https:\/\/doi.org:10.1016\/j.xinn.2021.100141.","journal-title":"Innov (Camb)"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1039\/c5mb00663e","article-title":"ReactomePA: an R\/Bioconductor package for reactome pathway analysis and visualization","volume":"12","author":"Yu G","year":"2016","unstructured":"Yu G, He QY. ReactomePA: an R\/Bioconductor package for reactome pathway analysis and visualization. Mol Biosyst. 2016;12:477\u20139. https:\/\/doi.org:10.1039\/c5mb00663e.","journal-title":"Mol Biosyst"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon A","year":"2015","unstructured":"Liberzon A, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325. https:\/\/doi.org:10.1016\/j.cels.2015.12.004.","journal-title":"Cell Syst"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida W","year":"2019","unstructured":"Abida W, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019;116:11428\u201336. https:\/\/doi.org:10.1073\/pnas.1902651116.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson D","year":"2015","unstructured":"Robinson D, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215\u201328. https:\/\/doi.org:10.1016\/j.cell.2015.05.001.","journal-title":"Cell"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.1158\/0008-5472.CAN-06-3849","article-title":"Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo","volume":"67","author":"Challita-Eid PM","year":"2007","unstructured":"Challita-Eid PM, et al. Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. Cancer Res. 2007;67:5798\u2013805. https:\/\/doi.org:10.1158\/0008-5472.CAN-06-3849.","journal-title":"Cancer Res"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"9502","DOI":"10.1074\/jbc.RA120.013690","article-title":"Cryo-electron microscopy structure and potential enzymatic function of human six-transmembrane epithelial antigen of the prostate 1 (STEAP1)","volume":"295","author":"Oosterheert W","year":"2020","unstructured":"Oosterheert W, Gros P. Cryo-electron microscopy structure and potential enzymatic function of human six-transmembrane epithelial antigen of the prostate 1 (STEAP1). J Biol Chem. 2020;295:9502\u201312. https:\/\/doi.org:10.1074\/jbc.RA120.013690.","journal-title":"J Biol Chem"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1158\/0008-5472.can-03-3856","article-title":"The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells","volume":"64","author":"Nahta R","year":"2004","unstructured":"Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004;64:2343\u20136. https:\/\/doi.org:10.1158\/0008-5472.can-03-3856.","journal-title":"Cancer Res"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina SO","year":"2003","unstructured":"Doronina SO, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21:778\u201384. https:\/\/doi.org:10.1038\/nbt832.","journal-title":"Nat Biotechnol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1349-7006.1995.tb02468.x","article-title":"A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo","volume":"86","author":"Mitsui I","year":"1995","unstructured":"Mitsui I, et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res. 1995;86:776\u201382. https:\/\/doi.org:10.1111\/j.1349-7006.1995.tb02468.x.","journal-title":"Jpn J Cancer Res"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2402701","DOI":"10.1080\/19420862.2024.2402701","article-title":"Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors","volume":"16","author":"Hale G","year":"2024","unstructured":"Hale G, De Vos J, Davy AD, Sandra K, Wilkinson I. Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors. MAbs. 2024;16:2402701. https:\/\/doi.org:10.1080\/19420862.2024.2402701.","journal-title":"MAbs"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1038\/s41467-018-05366-3","article-title":"A reliable murine model of bone metastasis by injecting cancer cells through caudal arteries","volume":"9","author":"Kuchimaru T","year":"2018","unstructured":"Kuchimaru T, et al. A reliable murine model of bone metastasis by injecting cancer cells through caudal arteries. Nat Commun. 2018;9:2981. https:\/\/doi.org:10.1038\/s41467-018-05366-3.","journal-title":"Nat Commun"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-25-0682","article-title":"Immune reprogramming of tumor microenvironments by cytotoxic antibody-drug conjugate payloads","author":"Chakravorty S","year":"2025","unstructured":"Chakravorty S, et al. Immune reprogramming of tumor microenvironments by cytotoxic antibody-drug conjugate payloads. Mol Cancer Ther. 2025. https:\/\/doi.org:10.1158\/1535-7163.MCT-25-0682.","journal-title":"Mol Cancer Ther"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40425-018-0464-1","article-title":"A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer","volume":"7","author":"D'Amico L","year":"2019","unstructured":"D'Amico L, et al. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. J Immunother Cancer. 2019;7:16. https:\/\/doi.org:10.1186\/s40425-018-0464-1.","journal-title":"J Immunother Cancer"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta R","year":"2009","unstructured":"Elgueta R, et al. Molecular mechanism and function of CD40\/CD40L engagement in the immune system. Immunol Rev. 2009;229:152\u201372. https:\/\/doi.org:10.1111\/j.1600-065X.2009.00782.x.","journal-title":"Immunol Rev"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004704","article-title":"GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies","volume":"10","author":"Pascual-Pasto G","year":"2022","unstructured":"Pascual-Pasto G, et al. GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies. J Immunother Cancer. 2022;10. https:\/\/doi.org:10.1136\/jitc-2022-004704.","journal-title":"J Immunother Cancer"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1172\/JCI127471","article-title":"cGAS\/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity","volume":"129","author":"Wang Z","year":"2019","unstructured":"Wang Z, et al. cGAS\/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity. J Clin Invest. 2019;129:4850\u201362. https:\/\/doi.org:10.1172\/JCI127471.","journal-title":"J Clin Invest"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2021.06.031","article-title":"Inhibition of topoisomerase I shapes antitumor immunity through the induction of monocyte-derived dendritic cells","volume":"520","author":"Lee JM","year":"2021","unstructured":"Lee JM, et al. Inhibition of topoisomerase I shapes antitumor immunity through the induction of monocyte-derived dendritic cells. Cancer Lett. 2021;520:38\u201347. https:\/\/doi.org:10.1016\/j.canlet.2021.06.031.","journal-title":"Cancer Lett"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"113503","DOI":"10.1016\/j.celrep.2023.113503","article-title":"Engineering CD276\/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability","volume":"42","author":"Feng Y","year":"2023","unstructured":"Feng Y, et al. Engineering CD276\/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability. Cell Rep. 2023;42:113503. https:\/\/doi.org:10.1016\/j.celrep.2023.113503.","journal-title":"Cell Rep"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1038\/s41591-025-03783-8","article-title":"CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial","volume":"31","author":"Liu J","year":"2025","unstructured":"Liu J, et al. CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial. Nat Med. 2025;31:3028\u201336. https:\/\/doi.org:10.1038\/s41591-025-03783-8.","journal-title":"Nat Med"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","article-title":"Mechanisms of Therapeutic Antitumor Monoclonal Antibodies","volume":"81","author":"Tsao LC","year":"2021","unstructured":"Tsao LC, Force J, Hartman ZC. Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. Cancer Res. 2021;81:4641\u201351. https:\/\/doi.org:10.1158\/0008-5472.CAN-21-1109.","journal-title":"Cancer Res"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1186\/s12967-025-06519-x","article-title":"Macrophages in prostate cancer: dual roles in tumor progression and immune evasion","volume":"23","author":"Liu R","year":"2025","unstructured":"Liu R, et al. Macrophages in prostate cancer: dual roles in tumor progression and immune evasion. J Transl Med. 2025;23:615. https:\/\/doi.org:10.1186\/s12967-025-06519-x.","journal-title":"J Transl Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/pros.22742","article-title":"Distribution of metastatic sites in patients with prostate cancer: A population-based analysis","volume":"74","author":"Gandaglia G","year":"2014","unstructured":"Gandaglia G, et al. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. Prostate. 2014;74:210\u20136. https:\/\/doi.org:10.1002\/pros.22742.","journal-title":"Prostate"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9194287\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9194287\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:00:32Z","timestamp":1789401632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9194287\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":54,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9194287\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s12967-026-08927-z","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2026,4,24]]},"subtype":"preprint"}}